Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Capital Expenditures: 2022-2025

  • Corvus Pharmaceuticals' Capital Expenditures was N/A to $113,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $448,000, marking a year-over-year change of. This contributed to the annual value of $34,000 for FY2023, which is 87.36% down from last year.
  • According to the latest figures from Q2 2025, Corvus Pharmaceuticals' Capital Expenditures is $113,000, which was up 213.89% from $36,000 recorded in Q1 2025.
  • Corvus Pharmaceuticals' Capital Expenditures' 5-year high stood at $265,000 during Q3 2022, with a 5-year trough of $34,000 in Q1 2023.
  • For the 2-year period, Corvus Pharmaceuticals' Capital Expenditures averaged around $61,000, with its median value being $36,000 (2025).